Quarterly report pursuant to Section 13 or 15(d)

Organization and Description of Business (Narrative) (Details)

v3.23.1
Organization and Description of Business (Narrative) (Details)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended
Oct. 31, 2021
USD ($)
Mar. 31, 2023
company
$ / shares
Dec. 31, 2022
$ / shares
Number of partner companies that are publicly traded | company   4  
Common Stock, par value | $ / shares   $ 0.001 $ 0.001
Number of partner companies that have consummated strategic partnerships with industry leaders | company   2  
Caelum | AstraZeneca      
Deconsolidation of consolidated partner company, percentage deconsolidated 100.00%    
Deconsolidation of consolidated partner company, upfront payment | $ $ 150    
Caelum | AstraZeneca | Maximum      
Deconsolidation of consolidated partner company, contingent payment | $ $ 350